Burkitt-like lymphoma is an aggressive disease, but at the Israeli Ichilov clinic, thanks to years of accumulated experience and advanced technologies, treatment of this pathology achieves high success rates even in complex cases. The most modern international protocols are applied here, and leading specialists continuously improve approaches based on global achievements. An individual therapy plan is built considering the characteristics of the tumor and the patient's condition, which allows for maximum effectiveness.
Treatment combines intensive chemotherapy, immunotherapy, and targeted drugs tailored to the individual. The conditions in the clinic are carefully designed for a comfortable stay, and if necessary, personal accompaniment services for foreign patients are available. As a result, even with rapid disease progression, the chances of complete remission and long-term control remain high, instilling confidence in the right choice.
About the Disease
Burkitt-like lymphoma is a highly malignant lymphoproliferative disease with aggressive dynamics. Despite its external similarity to the classical variant of Burkitt lymphoma, this pathology is categorized separately due to the absence of typical molecular-genetic markers, such as MYC rearrangement.
Three main clinical forms of Burkitt-like lymphoma are distinguished: sporadic, endemic, and associated with immunodeficiency states.
Causes
- HIV infection
- Epstein-Barr virus (EBV)
- Immunosuppression (transplantation, autoimmune diseases)
- Genetic disorders (rarely)
- Unknown factors in sporadic form
Symptoms
- Rapid enlargement of lymph nodes
- Abdominal pain, bloating
- Fever, night sweats
- Weight loss
- Weakness, fatigue
- Anemia, bleeding
- Intestinal obstruction
- Neurological disorders
Send your records — an Ichilov physician will reply within 1–2 days, free of charge.
Treatment Methods
At Ichilov, the choice of treatment methods for Burkitt-like lymphoma is based on the results of immunohistochemical and molecular-genetic analysis, which determine the exact subtype of the disease and the aggressiveness of the tumor, allowing for the formation of an intensive therapeutic strategy considering prognostic factors and risks of recurrence.
Intensive Multi-component Chemotherapy
From the moment of diagnosis of Burkitt-like lymphoma, immediate initiation of aggressive treatment is required due to the high rate of tumor cell division. Protocols include combinations of alkylating agents, antimetabolites, and topoisomerase inhibitors that act on various phases of the cell cycle. Chemotherapy cycles alternate with short intervals, not allowing the tumor to recover between courses. The intensity of the regimen requires constant monitoring of blood parameters and internal organ function, allowing for timely dose adjustments and prevention of critical complications.
Prevention of Neuroleukemia
Considering the high tendency of Burkitt-like lymphoma to affect the central nervous system, even in the absence of clinical signs of involvement of the meninges, prophylactic administration of cytostatics begins. Intrathecal administration of drugs directly into the spinal canal via lumbar puncture creates therapeutic concentrations in the cerebrospinal fluid, where systemic drugs penetrate insufficiently due to the blood-brain barrier. The procedure is repeated several times according to the protocol, providing reliable protection of nervous tissue from metastasis, which is critical for preventing neurological complications and maintaining long-term prognosis.
Targeted Immunotherapy
Molecular profiling of the tumor can identify specific antigens on the surface of malignant B-lymphocytes, opening the possibility for the use of monoclonal antibodies. These biological agents selectively bind to tumor cells and initiate mechanisms for their destruction through complement activation or recruitment of natural killers. The addition of targeted agents to standard chemotherapy enhances the anti-tumor effect without a proportional increase in toxicity. At Ichilov, effectiveness monitoring is conducted using PET-CT, allowing for the assessment of metabolic activity of residual foci and adjustment of therapy at early stages in case of insufficient response.
High-dose Consolidation Chemotherapy
After achieving primary remission, the risk of recurrence remains significant due to the biological characteristics of Burkitt-like lymphoma, necessitating additional intensification of treatment. Consolidation cycles use increased doses of cytostatics to eliminate minimal residual disease, which may be a source of disease return. This stage is particularly important for patients with unfavorable prognostic factors, such as high levels of lactate dehydrogenase or massive tumor involvement at the time of diagnosis. Supportive therapy includes intensive hydration and medications to prevent tumor lysis syndrome, which occurs with massive cell death.
Autologous Stem Cell Transplantation
In cases with particularly high risk or early recurrence after the first line of therapy, the possibility of transplanting the patient's own hematopoietic stem cells is considered. They are collected from peripheral blood by apheresis during remission when the bone marrow is free of tumor cells. The patient then receives myeloablative chemotherapy at doses that completely destroy bone marrow hematopoiesis along with any possible residual lymphoma. The return of the patient's own stem cells allows for the restoration of the hematopoietic system, and the post-transplant period requires staying in a specialized unit with monitoring of infection risks until complete engraftment of the transplant.
Radiation Therapy for Areas of Massive Involvement
When large tumor conglomerates of lymph nodes or extranodal foci are identified at the time of diagnosis, local irradiation of these areas may be prescribed after chemotherapy is completed. Modern IMRT technologies ensure precise delivery of radiation doses to residual formations, minimizing impact on surrounding healthy tissues. The decision on the necessity of radiation therapy is made individually based on the results of control imaging and assessment of metabolic activity in areas of primary involvement. This method enhances local control in anatomical areas where achieving complete remission with chemotherapy alone is complicated due to the size of the formations.
Supportive and Accompanying Therapy
The aggressiveness of treatment protocols for Burkitt-like lymphoma makes managing side effects an integral part of the therapeutic strategy at Ichilov. Granulocyte colony-stimulating factors reduce the duration of neutropenia and lower the risk of life-threatening infections, while modern antiemetic regimens ensure control of nausea even with highly emetogenic regimens. Prevention of tumor lysis syndrome includes forced diuresis, urine alkalinization, and the use of medications that break down uric acid. Nutritional support involving dietitians helps maintain body mass and metabolic status, which is critical for tolerating intensive courses and recovery speed between them.
CAR-T Cell Therapy
In cases of refractoriness to standard regimens or recurrence after transplantation, innovative methods of cellular immunotherapy come into play. The patient's own T-lymphocytes are collected from the blood, genetically modified in a specialized laboratory by adding a chimeric antigen receptor that recognizes tumor cells. After a period of proliferation, the modified cells are returned to the patient, where they actively seek and destroy the lymphoma.
- Radiation Therapy
- Bone Marrow Transplantation in Israel
- Chemotherapy
- CAR-T Therapy
Diagnostic Methods for the Disease
Considering the high aggressiveness and progression rates of Burkitt-like lymphoma, conducting rapid and highly accurate diagnostics becomes the foundation of treatment, allowing for the adaptation of the therapeutic strategy to the specific characteristics of the neoplasm. At Ichilov, all studies are performed on high-precision modern equipment, and the entire diagnostic plan is formed in advance and carried out within a short time frame.
First Day
Upon arrival at the clinic, the patient immediately sees the attending physician. The specialist thoroughly collects the medical history, conducts a detailed examination, assesses the condition of the lymph nodes, and prescribes a series of tests to obtain a complete picture of the disease.
Second Day
On this day, all key diagnostic procedures are performed.
- Complete blood count with leukocyte formula
- Biochemical blood analysis
- Blood test for tumor markers (including LDH)
- Serological tests for HIV and EBV
- PCR diagnostics for Epstein-Barr virus
- Ultrasound of lymph nodes
- CT of the neck, chest, abdomen, and pelvis
- PET-CT
- Lymph node biopsy (fine-needle or open)
- Histological and immunohistochemical examination
- Cytogenetic analysis and FISH for MYC rearrangements
Third Day
The attending physician gathers a council of specialists (oncologists, hematologists, pathomorphologists, radiologists), during which all results are discussed. This allows for the formulation of the most accurate and relevant individual treatment plan.
- Computed Tomography
- Diagnostics — PET CT
- Ultrasound
- Biopsy and Histological Studies
- Blood Biochemistry
How Much Does Treatment Cost in Israel
The final cost of treating Burkitt-like lymphoma is determined by the complexity of the diagnostic program, the type of intensive therapy used, and the necessity of using expensive biological agents. The price is significantly influenced by the volume of necessary laboratory tests and the total duration of hospitalization.
For a detailed calculation of the cost applicable to a specific case, it is advisable to contact a consultant at the phone number provided on the website. The specialist will provide a preliminary estimate, clarify the payment procedure, and assist in planning the organizational stages of the trip.
Advantages of Treatment in Israel
- Recognized experts in the field of aggressive hematological pathologies by the global community
- Super-precise diagnostic technologies for rapid verification of rare tumor subtypes
- The most modern protocols for high-dose chemotherapy and innovative immunotherapy
- Personalized approach to developing a treatment strategy for each patient
- Maximally comfortable conditions for stay with accompaniment at all stages
Even before arriving at the clinic, it is possible to order a remote consultation with a leading specialist in video format. Following the conversation, qualified recommendations, complete answers to medical questions, and detailed information about the application of the latest global technologies are provided.